Recent News

• 06.05.2025 - Jefferies 2025 Global Healthcare Conference
• 06.05.2025 - Jefferies 2025 Global Healthcare Conference
• 06.03.2025 - Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
• 06.03.2025 - Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
• 05.21.2025 - RBC Capital Markets 2025 Global Healthcare Conference
• 05.21.2025 - RBC Capital Markets 2025 Global Healthcare Conference
• 05.14.2025 - Jasper Therapeutics to Present at Upcoming Investor Conferences
• 05.14.2025 - Jasper Therapeutics to Present at Upcoming Investor Conferences
• 05.12.2025 - Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.12.2025 - Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 05.19.2025 - DEF 14A Other definitive proxy statements
• 05.19.2025 - ARS Annual Report to Security Holders
• 05.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - 8-K Current report
• 03.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.26.2025 - EFFECT Notice of Effectiveness